Positive Clinical Data for PBI-1402 Presented at the Annual Congress of the European Hematology Association

ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today presented results on
its orally-active PBI-1402 compound in clinical trial in patients with
chemotherapy-induced anemia ("CIA") at the 13th Congress of the European
Hematology Association held in Copenhagen, Denmark this week.


Dr. Lyne Gagnon, ProMetic's Director R&D, Biology, presented data on PBI-1402 in
a poster entitled "PBI-1402 increases hemoglobin level and red blood cell count
in chemotherapy-induced anemia". Results demonstrated that a once daily oral
treatment of PBI-1402 induces a significant increase in hemoglobin ("Hb") level,
red blood cell ("RBC") count and hematocrit ("Ht") in CIA patients. Furthermore,
results suggest that PBI-1402 can reduce the need for RBC transfusion, since
only 6% of patients in the clinical trial required transfusion.


"Subsequent positive data compiled from the 28 patients having completed the
PBI-1402 CIA clinical trial include the fact that 26 of these patients did not
require RBC transfusions while maintaining their full chemotherapy regimen. This
data further supports that PBI-1402's current performance is in line with the
Food and Drug Administration's ("FDA") recommendation of reducing patient need
for RBC transfusions," states Mr. Pierre Laurin, ProMetic's President and Chief
Executive Officer. "Additionally, PBI-1402 offers the added advantage of oral
dosing which allows for a convenient management of anemia without interference
with other treatments received by the CIA patients."


In the March 13, 2008 briefing document, the FDA's Oncologic Drugs Advisory
Committee emphasized that the primary objective of treating CIA patients with
erythropoiesis-stimulating agents ("ESAs") as being the ability to reduce the
need for RBC transfusions. Approximately 50% of anemic patients receiving
chemotherapy require RBC transfusions, and 20%-25% of patients treated with ESAs
still require RBC transfusions.


About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a
biopharmaceutical company specialized in the research, development, manufacture
and marketing of a variety of commercial applications derived from its
proprietary Mimetic Ligand(TM) technology. This technology is used in
large-scale purification of biologics and the elimination of pathogens. ProMetic
is also active in therapeutic drug development with the mission to bring to
market effective, innovative, lower cost, less toxic products for the treatment
of hematology and cancer. Its drug discovery platform is focused on replacing
complex, expensive proteins with synthetic "drug-like" protein mimetics.
Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the
U.S. and Canada, manufacturing facilities in the U.K. and business development
activities in the US, Europe, Asia and in the Middle-East.


Forward Looking Statements

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations on page 21 of ProMetic's Annual Information Form for the year ended
December 31, 2007, under the heading "Risk Factors". As a result, we cannot
guarantee that any forward-looking statement will materialize. We assume no
obligation to update any forward-looking statement even if new information
becomes available, as a result of future events or for any other reason, unless
required by applicable securities laws and regulations.

Cornerstone Industries International Inc. (Tier2) (TSXV:CIA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024